I n transfusing patients with red blood cells, physicians and surgeons aim to enhance the circulatory oxygen-carrying capacity that has been compromised due to blood loss or a hematological disorder. In general, bleeding and transfusion strongly correlate with adverse outcomes in patients undergoing percutaneous coronary intervention (PCI) (1, 2) . Understandably, these negative reports have culminated in a higher threshold among physicians to prescribe blood transfusion (3) . Nonetheless, there is considerable variation in transfusion practices in U.S. hospitals, and current transfusion guidelines reflect the uncertainty stemming from the available evidence (3, 4) . The field of interventional cardiology is no exception to this, and the ideal place of blood transfusion around the time of PCI is unclear.
In this issue of JACC: Cardiovascular Interventions, Figure 1) . The main study outcomes of interest are mortality and bailout transfusion.
Although the meta-analysis by Kwok et al. (5) serves as a stark reminder of the potential adverse prognostic effects of transfusion, the wait continues for the ideal prospective, randomized trial that will definitively alter our practice and allay our fears.
Until then, clinicians should continue to adopt best practice with prudent use of transfusion based on the severity of patient presentation. More importantly, it is paramount that a bleeding avoidance strategy (with upfront risk stratification as well as active procedural measures) be meticulously adopted in all invasive procedures to prevent significant acute anemia. This may be the single most important take-home message from the present comment!
